Cargando…
Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature
Introduction: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. Case Report: We present the case of a 62-year-old woman with a past medical history...
Autores principales: | Turner, Jessica, Begum, Tahmina, Smalligan, Roger D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011300/ https://www.ncbi.nlm.nih.gov/pubmed/27635409 http://dx.doi.org/10.1177/2324709616663231 |
Ejemplares similares
-
Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
por: Fukuda, Masafumi, et al.
Publicado: (2020) -
Diabetic Ketoacidosis as First Presentation of Latent Autoimmune Diabetes in Adult
por: Nadhem, Omar, et al.
Publicado: (2015) -
Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
por: Adachi, Junichiro, et al.
Publicado: (2017) -
Canagliflozin-associated diabetic ketoacidosis: a case report
por: Chai, Peter R., et al.
Publicado: (2017) -
Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels
por: Vadi, Sonali, et al.
Publicado: (2017)